Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 6/20 | 0.56 |
| ▸ | CTSL | P07711 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27482719 | 0.89 | NR1H4 (0.46) | CTSBCTSLCTSSCTSKALDH1A1 | |
| SCHEMBL7465041 | 0.87 | MMP2 (0.54) | CTSBCTSLCTSSCTSKALDH1A1 | |
| SCHEMBL7462265 | 0.84 | CTSL (0.56) | CTSBCTSLCTSSCTSKALDH1A1 | |
| SCHEMBL27515259 | 0.84 | MAOA (0.47) | ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL7472149 | 0.83 | CTSK (0.52) | CTSKRAB9AMEN1KMT2A | |
| SCHEMBL7378621 | 0.80 | MAPT (0.45) | CTSBCTSLCTSSCTSKALDH1A1 | |
| SCHEMBL13753279 | 0.80 | MLYCD (0.64) | CTSBCTSLCTSSCTSKALDH1A1 | |
| SCHEMBL13753268 | 0.80 | MLYCD (0.64) | CTSBCTSLCTSSCTSKALDH1A1 | |
| SCHEMBL40780 | 0.79 | CTRB1 (0.58) | CTSBCTSLCTSSCTSKRAB9A | |
| SCHEMBL40779 | 0.79 | CTRB1 (0.58) | CTSBCTSLCTSSCTSKRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | claimed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | claimed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | claimed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| CN-1341590-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | claimed |
| CN-1255119-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-05-31 | — | — | CN | claimed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | claimed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | claimed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | claimed |
| EP-0253882-A4 | ACYLATED CYANAMIDE COMPOSITION. | UNIV MINNESOTA (US) | 1990-06-27 | — | — | EP | claimed |
| US-4870056-A | DETERRENTS OF ALCOHOL ABUSE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1989-09-26 | — | — | US | claimed |
| EP-0253882-A1 | ACYLATED CYANAMIDE COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1988-01-27 | — | — | EP | claimed |
| WO-1987004348-A1 | ACYLATED CYANAMIDE COMPOSITION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1987-07-30 | — | — | WO | claimed |
| US-9026372-B2 | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-0253882-A1 | ACYLATED CYANAMIDE COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1988-01-27 | — | — | EP | disclosed |
| WO-1987004348-A1 | ACYLATED CYANAMIDE COMPOSITION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | CTSB 13/4885CTSL 4/4885CTSS 10/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSB 4/4885CTSL 14/4885CTSS 8/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSB 4/4885CTSL 14/4885CTSS 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.